依达拉奉治疗缺血性脑卒中的效果研究

Effect of Edaravone on Ischemic Stroke

目的探讨依达拉奉治疗缺血性脑卒中的效果。方法研究对象来自于2017年1月—2019年12月本院收治缺血性脑卒中患者,共计98例,以随机数字表法进行分组,每组49例,其中对照组行对症治疗与溶栓治疗,研究组在对照组的基础上应用依达拉奉治疗,观察并比较两组的疗效、治疗前与治疗后C反应蛋白(CRP)与白细胞介素(IL-6)水平及不良反应。结果研究组治疗总有效率为93.88%,高于对照组的79.59%,比较差异有统计学意义(P <0.05);治疗后,研究组IL-6、CRP水平均低于对照组,差异均有统计学意义(P <0.01);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论依达拉奉治疗缺血性脑卒中效果确切,值得临床推广。

Objective To explore the effect of edaravone in the treatment of ischemic stroke.Methods 98 patients with ischemic stroke as the research subjects admitted to our hospital from January 2017 to December 2019,and they were divided into control group and study group according to the random number table method,49 cases each.The control group was treated with routine symptomatic and thrombolytic therapy,and the study group was treated with edaravone on the basis of the control group.The curative effect,changes of C-reactive protein(CRP)and interleukin-6(IL-6)before and after treatment,as well as adverse reactions were observed and compared between the two groups.Results The total effective rate of treatment in the study group was 93.88%,higher than 79.59%in the control group,the difference was statistically significant(P<0.05).After treatment,the levels of IL-6 and CRP in the study group were lower than those in the control group,and the differences were statistically significant(P<0.01).The difference in the incidence of adverse reactions between the two groups was not statistically significant(P>0.05).Conclusion Edaravone is effective in the treatment of ischemic stroke and is worthy of clinical promotion.